Abstract | AIMS: MATERIALS & METHODS: In this observational, single-center study, a total of 48 patients with solid tumors were treated with a new biosimilar G-CSF (Zarzio(®)) for 4-14 days from the day following the end of chemotherapy. RESULTS: Between October 2010 and July 2011, biosimilar G-CSF was administered as primary prophylaxis in 37 patients and as secondary prophylaxis in 11 patients in our clinic. The median length of G-CSF administration was 7 days (range: 1-12 days). Three cases of febrile neutropenia were reported: two in patients with prostate adenocarcinoma and one in a patient with pulmonary squamous cell carcinoma and multiple secondary skeletal lesions. These patients were treated with antibiotics and improved within 24 h without the need for hospitalization. Nonfebrile grade 4 neutropenia was observed in a further six patients. CONCLUSION: Our experience indicates that the use of biosimilar G-CSF is safe and effective at reducing neutropenic complications in patients with solid tumors and may be associated with cost savings.
|
Authors | Nello Salesi, Barbara Di Cocco, Maria Colonna, Enzo Veltri |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 8
Issue 5
Pg. 625-30
(May 2012)
ISSN: 1744-8301 [Electronic] England |
PMID | 22401144
(Publication Type: Journal Article)
|
Chemical References |
- Biosimilar Pharmaceuticals
- Granulocyte Colony-Stimulating Factor
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Biosimilar Pharmaceuticals
(administration & dosage, adverse effects, therapeutic use)
- Female
- Granulocyte Colony-Stimulating Factor
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Male
- Middle Aged
- Neoplasms
(complications, drug therapy)
- Neutropenia
(chemically induced, prevention & control)
- Treatment Outcome
|